TP53 and ovarian carcinoma: The ability of AGR2 to suppress p53 activity could be explained, in part, in an environment or tumor which is lower frequency of p53 mutations, for example breast cancer,33, 34 a disease where AGR2 is overexpressed and p53 wild‐type is maintained in a majority of cases.8, 35, 36 Conversely, where p53 has a high frequency of mutation, as ovarian cancer,5, 6 the suppression of p53 from AGR2 pathway may be less active.7, 29